Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVJF) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Teva Pharmaceutical Industries (TEVJF) over the last 17 years, with Q4 2025 value amounting to $165.0 million.

  • Teva Pharmaceutical Industries' Cash from Investing Activities fell 1831.68% to $165.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $737.0 million, marking a year-over-year decrease of 694.44%. This contributed to the annual value of $737.0 million for FY2025, which is 694.44% down from last year.
  • Per Teva Pharmaceutical Industries' latest filing, its Cash from Investing Activities stood at $165.0 million for Q4 2025, which was down 1831.68% from $135.0 million recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Cash from Investing Activities high stood at $508.0 million for Q1 2021, and its period low was $135.0 million during Q3 2025.
  • Moreover, its 5-year median value for Cash from Investing Activities was $192.5 million (2023), whereas its average is $233.8 million.
  • In the last 5 years, Teva Pharmaceutical Industries' Cash from Investing Activities surged by 10158.73% in 2021 and then crashed by 6830.71% in 2022.
  • Over the past 5 years, Teva Pharmaceutical Industries' Cash from Investing Activities (Quarter) stood at $246.0 million in 2021, then plummeted by 31.71% to $168.0 million in 2022, then surged by 79.17% to $301.0 million in 2023, then crashed by 32.89% to $202.0 million in 2024, then dropped by 18.32% to $165.0 million in 2025.
  • Its last three reported values are $165.0 million in Q4 2025, $135.0 million for Q3 2025, and $236.0 million during Q2 2025.